FDA on Pace to Approve More New Drugs in 2012 Than the 30 Approved in 2011

Five Star Equities Provides Stock Research on CytRx and ZIOPHARM Oncology

Marketwired

NEW YORK, NY--(Marketwire - Nov 26, 2012) - The Biotech Industry has skyrocketed in 2012 as an increase in the number of new drug approvals has boosted investor optimism within the industry. The iShares Nasdaq Biotechnology Index Fund (IBB) and the SPDR S&P Biotech ETF (XBI) have both gained over 25 percent year-to-date. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on CytRx Corporation (NASDAQ: CYTR) and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP).

Access to the full company reports can be found at:
www.FiveStarEquities.com/CYTR
www.FiveStarEquities.com/ZIOP

"In 2011, the U.S. FDA approved 30 new drugs, compared to 21 in 2010," S&P Capital IQ wrote in a note. "Through September 2012, the year-to-date total was 22. We see an improving trend for FDA first cycle review approvals and a rise in the rate of new drug approvals for rare diseases, which we think is helping to boost investor sentiment for the agency, after years of criticism stemming from inconsistency in making and communicating its decisions."

Another key factor in the Biotech Industry's success has been the "patent cliff" major pharmaceuticals have faced in 2012. Major drug manufacturers have looked to biotech companies to help offset major revenue losses from expiring patents as it is less time consuming than developing new drugs through R&D.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

The CytRx oncology pipeline includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. The Company has held a positive meeting with the FDA to discuss a potential Phase 3 pivotal trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy, and is planning to submit a special protocol assessment related to this trial.

ZIOPHARM Oncology is a biopharmaceutical company focused on the discovery and development of new cancer therapies. The company's portfolio is comprised of five clinical-stage product candidates in all phases of development, as well as multiple research-stage candidates. An Independent Data Monitoring Committee has recently recommend completion of the company's Phase 3 trial of palifosfamide in first-line metastatic soft tissue sarcoma.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
www.FiveStarEquities.com/disclaimer

Contact:

Five Star Equities
Email Contact
View Comments (0)